Lev Osherovich

Lev Osherovich is a multifaceted professional with a strong background in science, venture capitalism, and biotechnology. He is currently the Founding Director at StealthCo and resides in Basel, Switzerland.2

Academic Background

Osherovich holds a Ph.D. in Biochemistry from the University of California, San Francisco, and a B.S. in Molecular and Cell Biology with a focus on Genetics from the University of California, Berkeley.

Professional Experience

Throughout his career, Lev Osherovich has held various significant positions:

• Founding Director at StealthCo (current role)2
• Partner at Delin Ventures
• Director of Innovation and Sourcing at Versant Ventures
• Academic Liaison at Versant Ventures
• Business Development Associate at Inception Sciences
• Senior Writer at BioCentury Publications
• Consulting Scientific Editor at Zenis Co., Ltd.

He has also served as a Postdoctoral Fellow at the University of California, San Francisco, and a Research Fellow at the University of Kent.

Expertise and Focus

Osherovich specializes in:

1. Identifying and evaluating early-stage drug discovery projects
2. Bridging the gap between academic research and industry
3. Discovering novel therapeutic opportunities

His LinkedIn profile describes him as a "Scientist, Company Builder, Investor" who leverages academic and industry knowledge to uncover unexpected therapeutic opportunities and launch new drug discovery ventures.2

Innovations and Contributions

Lev Osherovich has been involved in patent applications for various inventions, demonstrating his active role in scientific innovation and drug discovery.1

Recent Activities

Osherovich maintains an active presence on LinkedIn, sharing insights and commenting on developments in the biotech industry. Recent posts include discussions on:

• Simulations for experiments in drug discovery3
• Advancements in RNA-based therapies4
• Developments in cell therapy manufacturing5

Lev Osherovich's diverse experience and expertise make him a notable figure in the intersection of scientific research, biotechnology, and venture capitalism.